Myriad Genetics (NASDAQ:MYGN) Price Target Increased to $28.

Myriad Genetics (NASDAQ:MYGN – Free Report) had its target price increased by Piper Sandler from $23.00 to $28.00 in a research note issued to investors on Monday morning, Benzinga reports. The brokerage currently has a neutral rating on the stock. Several other equities research analysts have also issued reports on MYGN. Leerink Partnrs upgraded shares […]

Related Keywords

China , United States , Leerink Partnrs , Piper Sandler , Paulj Diaz , Blue Trust Inc , Ameritas Investment Partners Inc , Goldman Sachs Group , China Universal Asset Management Co , Genetics Company Profile , Genetics Inc , Allspring Global Investments Holdings , Myriad Genetics , Free Report , Get Free Report , Director Lee Nisley Newcomer , Universal Asset Management , Investment Partners , Global Investments Holdings , Clarus Wealth Advisors , Myrisk Hereditary Cancer Test , Germline Companion Diagnostic Test , Companion Diagnostic Test , Myriad Genetics Daily ,